Combined Intravenous and Oral Calcimimetic Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients Ineligible or Unwilling to Undergo Parathyroidectomy

View Full Paper

Ask AI

Bookmark

Combine IV and oral calcimimetic therapy significantly lowers iPTH levels in patients.
iPTH levels dropped from 980 pg/mL at baseline to 480 pg/mL after 24 weeks of treatment.
Prospective study in 110 adult hemodialysis patients demonstrated the effectiveness and tolerability of treatment.
Therapy provides a viable non-surgical option for managing secondary hyperparathyroidism in these patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Combined intravenous and oral calcimimetics reduced iPTH levels in hemodialysis patients, indicating effective management without surgery.

Bhatti et al. (2023) studied this question.

View Full Paper

Ask AI

Bookmark

Combined intravenous and oral calcimimetics reduced iPTH levels in hemodialysis patients, indicating effective management without surgery.